Abstract
Controlled randomized studies that compared surgery alone to adjuvant chemotherapy for gastric cancer were reviewed. The amount of residual tumor after surgery, selection of drug regimens, compliance with drug administration, and trial design seem to be responsible for the success of adjuvant chemotherapy. Though there are few beneficial regimens of adjuvant chemotherapy with statistical significance, single drug therapy with mitomycin C (MMC) and combination therapy with 5-fluorouracil (5FU) and methyl-CCNU, MMC/5FU/cytosine arabinoside (MFC), and 5FU/Adriamycin/MMC (FAM) seem to have potential survival benefit for patients with curative surgery. Incorporation of new drugs into adjuvant or neoadjuvant chemotherapy might open a new aspect of multimodality therapy for gastric cancer.
Résumé
Ont été analysées iei les seules études contrôlées, randomisées, comparant la chirurgie seule et la chimiothérapie adjuvante dans le traitement du cancer gastrique. La masse de tissu résiduel restant après la chirurgie, la sélection de traitements chimiothéraquetiques, la compliance aux traitements et les structures des essais sont peut-être pour quelque chose dans le succés de la chimiothérapie adjuvante. Bien qu'il y ait peu d'études montrant des différences statistiquement significatives, les thérapies comportant seulement du MMC, celles combinant le 5 FU et le Méthyl CCNU, la MFC, et le FAM semblent pouvoir entraîner une survie supérieure dans les groupes comportant une chirurgie à visée curatrice. Incorporer de nouvelles drogues dans les prescriptions de chimiothérapie adjuvante ou néoadjuvante peut ouvrir de nouvelles perspectives dans le traitement du cancer gastrique à modalités multiples.
Resumen
Los estudios controlados y randomizados que emplean la cirugía sola como método de control de la quimioterapia adyuvante en el cáncer gástrico han sido revisados en forma exclusiva. La cantidad de tumor residual luego de la cirugía, la selección de los regimenes de droga antineoplásica el cumplimiento en la administración de la droga y el diseño del ensayo clínico, parecen ser los factores responsables del éxito de la quimioterapia adyuvante. Aunque sólo existen pocos regímenes que hayan demostrado beneficio con significación estadística, el MMC único, la combinación de 5-FU y Metil-CCNU, el MFC y el FAM, parecen poseer un beneficio potencial de sobrevida en los grupos de pacientes sometidos a cirugía curativa. La incorporación de nuevas drogas a la quimioterapia adyuvante o neoadyuvante podría abrir un nuevo aspecto en la terapia multimodal en el cáncer gástrico.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nakajima, T., Nishi, M.: Adjuvant chemotherapy, immunochemotherapy, and neoadjuvant therapy for gastric cancer in Japan. Contemp. Issues Clin. Oncol. 8:125, 1988
Nakajima, T.: Adjuvant chemotherapy for gastric cancer in Japan: present status and suggestions for rational clinical trials. Jpn. J. Clin. Oncol. 20:30, 1990
Nakajima, T., Fukami, A., Ohashi, I., Kajitani, T.: Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin. C. Int. J. Clin. Pharmacol. 16:209, 1978
Longmire, W.P., Jr., Dixon, W.J.: The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann. Surg. 167:293, 1968
Dixon, W.J., Longmire, W.P., Jr., Holden, W.D.: Use of triethylene-thiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten year follow-up. Ann. Surg. 173:26, 1971
Serlin, O., Wolkoff, J., Amadeo, J.M., Keehn, R.J.: Use of 5-fluorodeoxyuridine(FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 24:223, 1969
Blokhina, N.G., Garin, A.M., Moros, L.V., et al.: Treatment with 5-fluorouracil in prophylaxis of relapse and metastasis of stomach cancer. Neoplasma 19:351, 1972
Imanaga, H., and Nakazato, H.: Results of surgery for gastric cancer and affect of adjuvant mitomycin C on cancer recurrence. World J. Surg. 1:213, 1977
Nakajima, T., Fukami, A., Ohashi, I., Kajitani, T.: Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int. J. Clin. Pharmacol. 16:209, 1978
Hattori, T., Mori, A., Hirata, K., Ito, I.: Five year survival rate of gastric cancer patients treated by gastrectomy, large dose mitomycin C, and/or allogeneic bone marrow transplantation. Gann 63:517, 1972
Alcobendas, F., Milla, A., Estape, J., Curto, J., Pera, C.: Mitomycin-C as adjuvant in resected gastric cancer. Ann. Surg. 198:13, 1983
Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49:1116, 1982
Higgins, G.A., Amadeo, J.H., Smith, D.E., Humphrey, E.W., Keehn, R.J.: Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma: a Veterans Administration Surgical Oncology Group report. Cancer 52: 1105, 1983
Engstrom, P.F., Lavin, P.T., Douglass, H.O., Jr., Brunner, K.W.: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 55:1868, 1985
Hugier, M., Destroyes, J-P., Baschet, C.: Gastric carcinoma treated by chemotherapy after resection: a controlled study. Am. J. Surg. 139: 197, 1980
Schreml, W., Schlag, P., Herfarth, C., et al.: Adjuvant 5-FU/BCNU in gastric carcinoma. In Adjuvant Therapy of Cancer IV, S.E. Jones, S.E. Salmon, editors. Grune & Stratton, Orlando, FL, 1984, pp. 441–448
Ota, K., Kurita, S., Nishimura, M., et al.: Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man. Cancer Chemother. Rep. 56:373, 1972
Nakajima, T., Fukami, A., Takagi, K., Kajitani, T.: Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J. Clin. Oncol. 10:187, 1980
Nakajima, T., Takahashi, T., Takagi, K., Kuno, K., Kajitani, T.: Comparison of 5-fluorouracil with Ftorafur in adjuvant chemotherapy with combined inductive and maintenance therapies for gastric cancer. J. Clin. Oncol. 2:1366, 1984
Fielding, J.W.L., Jagg, S.L., Jones, B.G., et al.: An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World J. Surg. 7:390, 1983
Macdonald, J.S., Woolley, P.V., Smythe, T., Ueno, W., Hoth, D., Schein, P.S.A.: 5-Fluorouracil, Adriamycin, and mitomycin C(FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44:42, 1979
Schein, P.S., Coombes, R.C., Chilvers, C., et al.: A controlled trial of FAM (5-FU, doxorubicin, and mitomycin-C) chemotherapy as adjuvant treatment for resected gastric carcinoma: an interim report. Proc. Am. Soc. Clin. Oncol. 5:79, 1985
Allum, W.H., Halliscey, M.T., Ward, L.C., Hockey, M.S.: A controlled prospective randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. Br. J. Cancer 60:739, 1989
Coombes, R.C., Schein, P.S., Chilvers, C.E.D., et al.: A randomized trial comparing adjuvant fluorouracil, doxirubicin, and mitomycin with no treatment in operable gastric cancer. J. Clin. Oncol. 8:1362, 1990
Krook, J.E., O'Connell, M.J., Wieand, H.R., et al.: A prospective, randomized evaluation of intensive course 5-fluorouracil plus doxorubiein as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67:2454, 1991
Lise, M., Nitti, D., Buyse, M., et al.: Adjuvant FAM2 in resectable gastric cancer. Anticancer Res. 9:1017, 1989
Klein, H.O., Wickrammanayake, P.D., Farrokh, G.R.: 5-Fluorouracil, adriamycin and methotrexate—a combination protocol (FAMtx) for treatment of metastasized stomach cancer. Proc. Am. Soc. Clin. Oncol. 5:84, 1986
Hermans, J., Bonenkamp, J.J., Boon, M.C., et al.: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11:1441, 1993
Preusser, P., Wilke, H., Achterrath, W., et al.: Phase II study with the combinaton etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol. 7:1310, 1989
Plukker, J.T., Mulder, N.H., Sleijfer, D.T., Grond, J., Verscheuren, R.C.J.: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br. J. Surg. 78:955, 1991
Kremer, B., Henne-Bruns, D., Weh, H.J., Effenberger, T.: Advanced gastric cancer: a new combined surgical and oncological approach. Hepatogastroenterology 36:23, 1989
Kato, S., Kinoshita, K., Sawa, T., et al.: Neoadjuvant chemotherapy in far advanced gastric carcinoma: effect of preoperative chemotherapy with PMUE (CDDP, MMC, UFT, etoposide). Gan to Kagakuryoho 17:391, 1990 (in Japanese)
Stahl, M., Wilke, H., Preusser, P.: Etoposide (E), leucovorin (L), 5-FU (ELF) in advanced gastric carcinoma(GC)—final results of a phase II study. In Abstracts of the European Conference on clinical Oncology, 1989, p. 0695
Akazawa, S., Yoshida, S.: The role of thymidylate synthetase in sequential dose of MTX and 5-FU for the advanced scirrhous type gastric cancer. Gan to Kagakuryouhou 15:1273, 1988 (in Japanese)
Kelsen, D., Lovett, D., Wong, J., et al.: Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J. Clin. Oncol. 10:269, 1992
Wadler, S., Lembersky, B., Atkins, M., Kirkwood, J., Petrelli, N.: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 9:1806, 1991
Surbone, A., Myers, C.E.: Regional therapies. In New Directions in Cancer Treatment, I. Magrath, editor. Springer-Verlag, Berlin, 1989, pp. 166–190
Speyer, J.L.: The rational behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin. Oncol. 12(Suppl. 4):23, 1985
Sugarbaker, P.H., Cunliffe, W.J., Belliveau, J., et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 16:83, 1989
Koga, S., Hamazoe, R., Maeta, M., Shimizu, N., Murakami, A., Wakatsuki, T.: Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232, 1988
Kaibara, N., Hamazoe, R., Iitsuka, Y., Maeta, M.: Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology 36:75, 1989
Fujimura, T., Yonemura, Y., Fuchida, S., et al.: Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65:65, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakajima, T. Review of adjuvant chemotherapy for gastric cancer. World J. Surg. 19, 570–574 (1995). https://doi.org/10.1007/BF00294725
Issue Date:
DOI: https://doi.org/10.1007/BF00294725